Published online before print August 12, 2004, doi: 10.1161/01.RES.0000142313.68389.92
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 29, 2003
Revised on August 3, 2004
Accepted on August 3, 2004
PPAR
Ligands Inhibit Rho/Rho Kinase Pathway by Inducing Protein Tyrosine Phosphatase SHP-2
Shu Wakino ;
From the Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
* To whom correspondence should be addressed. E-mail: saruta{at}sc.itc.keio.ac.jp.
Although peroxisome proliferator-activated receptor 
(PPAR) ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells (RASMC), Rho kinase stimulated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone, and these effects were explained by the inhibition of the Rho translocation to the cell membrane. We evaluated the role of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and SHP-2, a protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. Furthermore, 4-week treatment with pioglitazone lowered systolic blood pressure in spontaneously hypertensive rats (SHR) and suppressed the Rho/Rho kinase activity in aortic tissues isolated from SHR. Consistently, the expression of SHP-2 was upregulated in vascular tissues from pioglitazone-treated SHR. The phosphorylated Vav was increased in SHR, compared with that in normotensive Wistar-Kyoto rats (WKY), which was mitigated by pioglitazone. Finally, both basal and angiotensin II-stimulated levels of Rho kinase activity were greater in RASMC from SHR than those from WKY, and the enhanced Rho kinase activity was blocked by pioglitazone or troglitazone in both strains. Collectively, PPAR ligands inhibit the Rho/Rho kinase pathway through upregulation of cytosolic SHP-2 expression and inactivation of Vav, and may contribute to the hemodynamic, in addition to metabolic, action in hypertensive metabolic syndrome. The full text of this article is available online at http://circres.ahajournals.org.
Key words: PPAR
, Rho •
Rho kinase •
SHP-2 •
hypertension •
Vav •
pioglitazone •
troglitazone
This article has been cited by other articles:
 |
|
 |
|
  J. Bregeon, G. Loirand, P. Pacaud, and M. Rolli-Derkinderen Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1062 - C1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kimura and S. Eguchi Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells" Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1059 - C1061. [Full Text] [PDF]
|
|
|
|
|
|
K. B. Atkins, B. Irey, N. Xiang, and F. C. Brosius 3rd. A rapid, PPAR-{gamma}-dependent effect of pioglitazone on the phosphorylation of MYPT Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1151 - C1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chang, L. Villacorta, J. Zhang, M. T. Garcia-Barrio, K. Yang, M. Hamblin, S. E. Whitesall, L. G. D'Alecy, and Y. E. Chen Vascular Smooth Muscle Cell-Selective Peroxisome Proliferator-Activated Receptor-{gamma} Deletion Leads to Hypotension Circulation, April 28, 2009; 119(16): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tiffin, I. Okpechi, C. Perez-Iratxeta, M. A. Andrade-Navarro, and R. Ramesar Prioritization of candidate disease genes for metabolic syndrome by computational analysis of its defining phenotypes Physiol Genomics, September 17, 2008; 35(1): 55 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Smoak, J. Madenspacher, S. Jeyaseelan, B. Williams, D. Dixon, K. R. Poch, J. A. Nick, G. S. Worthen, and M. B. Fessler Effects of Liver X Receptor Agonist Treatment on Pulmonary Inflammation and Host Defense J. Immunol., March 1, 2008; 180(5): 3305 - 3312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Ramirez, D. Heilman, B. Morsey, R. Potula, J. Haorah, and Y. Persidsky Activation of Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Suppresses Rho GTPases in Human Brain Microvascular Endothelial Cells and Inhibits Adhesion and Transendothelial Migration of HIV-1 Infected Monocytes J. Immunol., February 1, 2008; 180(3): 1854 - 1865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.G. Ferrini, I. Kovanecz, S. Sanchez, D. Vernet, H.H. Davila, J. Rajfer, and N.F. Gonzalez-Cadavid Long-Term Continuous Treatment with Sildenafil Ameliorates Aging-Related Erectile Dysfunction and the Underlying Corporal Fibrosis in the Rat Biol Reprod, May 1, 2007; 76(5): 915 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kikuchi, M. Yamada, T. Imakiire, T. Kushiyama, K. Higashi, N. Hyodo, K. Yamamoto, T. Oda, S. Suzuki, and S. Miura A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats J. Endocrinol., March 1, 2007; 192(3): 595 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohtsu, H. Suzuki, H. Nakashima, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells Hypertension, October 1, 2006; 48(4): 534 - 540. [Full Text] [PDF]
|
|
|
|
 |
|
 G.-P. Sun, M. Kohno, P. Guo, Y. Nagai, K. Miyata, Y.-Y. Fan, S. Kimura, H. Kiyomoto, K. Ohmori, D.-T. Li, et al. Involvements of Rho-Kinase and TGF-beta Pathways in Aldosterone-Induced Renal Injury J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2193 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Henry, A. D'Aprile, G. Self, T. Hong, and T. S. Mann Inhibitors of Prostaglandin Transport and Metabolism Augment Protease-Activated Receptor-2-Mediated Increases in Prostaglandin E2 Levels and Smooth Muscle Relaxation in Mouse Isolated Trachea J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 995 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhu, S. Zhu, D. Liu, T. Cao, L. Wang, and M. Tepel Thiazide-Like Diuretics Attenuate Agonist-Induced Vasoconstriction by Calcium Desensitization Linked to Rho Kinase Hypertension, February 1, 2005; 45(2): 233 - 239. [Abstract] [Full Text] [PDF]
|
|